The ULTRALOW-VT study
Research type
Research Study
Full title
Transmurality of ventricular endocardial lesions created with UltraLow Temperature Cryoablation Technology; a prospective observational cohort study - The ULTRALOW-VT study
IRAS ID
335904
Contact name
Magdi Saba
Contact email
Sponsor organisation
St George's University Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Ventricular tachycardia (VT) is a dangerous heart rhythm disturbance that can cause sudden death. Medications are not particularly effective in treating this rhythm and are associated with significant side-effects. Catheter ablation can be used to treat VT and can decrease the need for therapies (shocks) that need to be delivered by a defibrillator in patients with VT. However, recurrences of VT are common. One of the reasons for failure of catheter ablation is the inability to create lesions which are deep enough to destroy the scar in the heart which is responsible for VT.
This study aims to use a state-of-the-art ablation system called ultra-low temperature cryoablation (ULTC). This technology uses -196oC nitrogen flow to rapidly freeze heart tissue to form durable, deeper ablation lesions compared to standard ablation catheters. In this study, we will investigate how deep the lesions delivered with this technology actually are and how the lesions affect the electrical signal both on the inside and outside of the heart, in order to better understand its impact.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
24/PR/1563
Date of REC Opinion
13 Jan 2025
REC opinion
Further Information Favourable Opinion